biostudies-literatureUnknown8(1)Polymeris AA<h4>Importance</h4>The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.<h4>Objective</h4>To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).<h4>Design, setting, and participants</h4>This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up. Participants included patients with atrial fibrillation-associated acute ischemic stroke, excluding those with therapeutic antJAMA network opene2456307https://www.ebi.ac.uk/biostudies/studies/S-EPMC11775740biostudies-literatureNet Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.PMC11775740Anwar IStoop WHarbison JStorton SNambiar VMcCabe JJDel Gaudio NNoone IRoyl GMedlin FDemeestere JDixon LWright FHussayni Husseini SASchelosky LDe Magistris ILMenezes BHemelsoet DInoue MAmina SMuller Seljeseth YRodic BSirimarco GNallasivan AEichel RKallmunzer BBonvin CPaiva Nunes AVehoff JAnjum TMatsubara SSipila JNiederhauser JOberndorfer SKoga MBhatia RKatan MMbroh JTrelle SBianco GStaykov DPsychogios MKelly PSreedharan SEGupta VIguchi YPap TVon Oertzen TJOlave Bersas IGralla JSato TAdeyemi AKHuded VBeyeler SAltmann MRutgers MPOlbert ELiesz ABradley DStetefeld HRKunieda TBornstein NMAlteheld LRani KMuller MGrimshaw BCharisse DDhasan ASibolt GDe Herdt VKhurana DKellert LVynckier JKahles TKulyk CNedeltchev KWilkinson ABerberich APeters NKrogias CDawson JGiudici DSelim MIhle-Hansen HWagner JSzabo KMako MOstanek SSandset ECde Sousa DALemmens RAlbert SJDanilo TMuller AGuzman-Gutierrez GWerring DHaley MHostens AArnold MThomalla GDelvoye FPeeters ABolognese MStrbian DCaporale CScutelnic APaliantonis AMarcelis ETiainen MVedamurthy ARichter DVanacker PHidalgo RStrambo DSchell MGdovinova ZRiebau SYperzeele LCollins RNtaios GSaukkonen AMKlimcikova KOnur OAMatzusono KMacha KGlobas CTakayuki FMarian RSharma AVMahajan NPinho E Melo TBorisova VPfeilschifter WVosko MVanhoorne ADymond HHumm AMZhang LRay SCiobanu CSlade PCassidy TParthasarathy RMulcahy RPolymeris AAFandler-Hofler SKellermair LKneihsl MPichler AAlonso AFung CMuresan IPDevroye AGoeldlin MBFischer UGentile LGreulich MBassetti CFujimoto SKrishnan MSargento-Freitas JLoos CSalanti GYakushiji YYoshimura SAsaf HFischer ADesfontaines PGalego SRyan DRaty SFenzl SMagrico MELAN InvestigatorsThomas HTatlisumak TPolavarapu NFerrari CTanaka RIype TMartinez-Majander NTanaka KPaciaroni MAdamou AZini AKaragkiozi EWhyte CBonati LHGoncalves Martins CSchlemm EJoan MacLeod MPolitz SPohner Skahjem MRenaud SWilson AMelancia DRezny-Kasprzak BClarke BDe Marchis GMSalerno AMorten Ronning ONabavi DGBranca MCosta TMichalski DLang MKumar VAbousleiman YPelz JClarke SGreisenegger SSmith GMSousa JABarber MSaxhaug Kristoffersen EMarto JPSchrammel DOrion DGbadamosh LYoshimoto TMcAlpine CSpetalen THisanao ASilimon NSylaja PNNakajima MCereda CWPope GGattringer TRingleb PKoundal HOffermann JMarnane MMichel PMosconi MGGumbinger CPandian JDShim GNair PGarcia-Pons MPamidimukkala VVanpanteghem IFalcou ASoltesova KAbdul-Rahim APoli SAbend SPencz ZFisch LWeder BJAnnamalai ALeker RRKato RHakim ASmith KCaracciolo NGHorvath TEsson DHealy LSeiffge DJfalseNet Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.<h4>Importance</h4>The net clinical effect of early vs later direct oral anticoagulant (DOAC) initiation after atrial fibrillation-associated ischemic stroke is unclear.<h4>Objective</h4>To investigate whether early DOAC treatment is associated with a net clinical benefit (NCB).<h4>Design, setting, and participants</h4>This was a post hoc analysis of the Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation (ELAN) open-label randomized clinical trial conducted across 103 sites in 15 countries in Europe, the Middle East, and Asia between November 6, 2017, and September 12, 2022, with a 90-day follow-up. Participants included patients with atrial fibrillation-associated acute ischemic stroke, excluding those with therapeutic ant2025-01-01T00:00:00Z2025 Jan2026-06-02T10:09:43.259Z2025-04-03T23:26:41.006ZS-EPMC117757403987403710.1001/jamanetworkopen.2024.56307